Q2 2020 Financial Results

Another quarter of strong performance across a diverse portfolio

Learn more

Our journey of impact

Come with us as we remember where we’ve been, and look forward to where we’re going.

Learn more

Latest news

If you are a member of the news media and have questions or need additional information, please contact our communications team.

Aug 03, 2020

Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial

Jul 31, 2020

AbbVie Reports Second-Quarter 2020 Financial Results

Jul 29, 2020

AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention

Jul 28, 2020

Third Pivotal Phase 3 Study Shows RINVOQ™ (upadacitinib) Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitis Patients
Read More

You must be logged in to view this item.

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?